Researchers and key players are focusing on the development of novel embolization products for the treatment of chronic diseases such as tumor, hemorrhage and others, which is expected to drive growth of the global embolization market over the forecast period.
For instance, in January 2021, MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, received the U.S. Food and Drug Administration approval for its PMA Supplement for the WEB 17 System, a new addition to the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms. The WEB 17 System, is designed with the latest MicroBraid technology, which features a lower profile delivery system compatible with the VIA 17 microcatheter, and includes additional device configurations.
Moreover, in November 2020, Fluidx Medical Technology, a U.S.-based embolic devices manufacturing company, introduced its novel GPX Embolic Device. It is an innovative embolic designed to combine the benefits of other embolics such as coils, particles, and liquids with simplified preparation, delivery, precision, and control leading to durable, long-term occlusions.
The global embolization market is estimated to be valued at US$ 1,433.6 million in 2020 and is expected to exhibit a CAGR of 8.1% over the forecast period (2020-2027).
Figure 1. Global Embolization Market Share (%) in Terms of Value, By Region, 2020
Increasing incidence of chronic diseases is expected to drive the market growth over the forecast period.
The increasing incidence of chronic diseases such as cancer, cardiovascular diseases, neurovascular diseases, and others is expected to drive growth of the global embolization market over the forecast period.
For instance, according to the World Health Organization statistics published in March 2021, cancer is the second leading cause of deaths globally, and is responsible for about 10 million deaths per year, across the globe, and about one in six deaths is due to cancer. Furthermore, according to the same source, an estimated 9.6 million deaths occurred due to cancer in 2018, globally.
Additionally, according to the Global Burden of Disease (GBD), an article published in the National Center for Biotechnology Information (NCBI) in July 2020, prevalence of ischemic heart disease is increasing. The GBD datasets analyzed that in 2020, the prevalence rate of ischemic heart disease was 1,655 per 100,000 global population, and is expected to exceed 1,845 by 2030.
Moreover, according to the Brain Aneurysm Foundation report 2020, there are almost 500,000 deaths worldwide each year caused by brain aneurysms, and half of the victims are younger than 50 years of age.
|Base Year:||2019||Market Size in 2020:||US$ 1,433.6 Mn|
|Historical Data for:||2016 to 2019||Forecast Period:||2020 to 2027|
|Forecast Period 2020 to 2027 CAGR:||8.1%||2027 Value Projection:||US$ 2,468.7 Mn|
IMBiotechnologies Ltd., ABK Biomedical Inc., EmboMedics, Guerbet, Boston Scientific Corporation, Medtronic Plc., Varian Medical Systems, Inc., Terumo Corporation, Merit Medical Systems, Inc., Cook Group, and Johnson & Johnson
|Restraints & Challenges:||
Figure 2. Global Embolization Market Share (%), by Product Type, 2020
Global Embolization Market– Impact of Coronavirus (Covid-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it as a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in over 122 million infected individuals worldwide, as of March 19, 2021.
The coronavirus or COVID-19 outbreak that started from Wuhan, China has spread across continents, affecting various industries globally. Supply of key materials such as probes required for interventional ablation have been severely disrupted due to forced quarantine, and imposed lockdowns in various countries. This has led to disruption in the link between regional warehouses, the transportation of materials between regions cannot be carried out successfully. This shortage of medical devices such as embolic coils, plugs required for embolization procedures have affected the supply chain of the global embolization market.
Moreover, the hospitals are delaying the uterine fibroid embolization of patients who are stable and the surgery can be postponed, or suggesting patients to undergo the treatment from outpatient’s services, to reduce the high risk of getting infected by the COVID-19.
Global Embolization Market Restraint
Product recall is a voluntary action taken, when laws administered by the U.S. Food and Drug Administration (FDA) are violated by manufacturers and distributors. The action is taken to protect public from the risk of injuries. Increasing number of product recalls of embolization products by various developers/manufacturers is expected to hinder growth of the market.
For instance, in March 2020, Medtronic Plc recalled Pipeline Flex Embolization Device (available in the U.S.) and Pipeline Flex Embolization Device with Shield Technology. The reason behind the recall of these two products is that there is a risk of the delivery system, which will fracture while placing the stent inside the patient. The U.S. FDA received 50 Medical Device Reports, with 10 injuries and one death regarding these embolization products from November 1, 2019 to March 1, 2020.
Major players operating in the global embolization market include IMBiotechnologies Ltd., ABK Biomedical Inc., EmboMedics, Guerbet, Boston Scientific Corporation, Medtronic Plc., Varian Medical Systems, Inc., Terumo Corporation, Merit Medical Systems, Inc., Cook Group, and Johnson & Johnson
Embolization is a minimally invasive treatment procedure that blocks one or more blood vessels or abnormal vascular channels. Embolization procedure requires various types of embolization particles such as radioembolization spheres, drug-eluting beads, microspheres, PVA particles (Polyvinyl Alcohol), and other products such as liquid embolic, plugs, and coils. Embolization procedure is used in the treatment of various chronic diseases such as cancer, uterine fibroid, and other complications of chronic diseases.
The academic and research institutes are focusing on the research and development in embolization PVA particles (polyvinyl alcohol), which is expected to drive the market growth over the forecast period
For instance, in April 2019, Washington University School of Medicine, a research university in the U.S., initiated the clinical trial study on Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA) on August 2019 and the clinical trial study is expected to be completed by January 1, 2022
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.